Figure 4

LMAb1could inhibit the proliferation of SKOV3-T. (A) LMAb1 could inhibit cell proliferation of SKOV3-T at a dose dependent manner. Similarly, the character of clone formation (B) and invasion/migration identified by transwell assay (C) could also be inhibited by LMAb1 in resistant SKOV3-T cells; (D & E) in vivo immunotherapy of LMAb1 combined with/without trastuzumab to SKOV3-T xenograft model in nude mice. D: mean tumor volume and E: overall survival rate; (F) LMAb1 could inhibit IGF-1R signal pathway transduction, for it could inhibit the MAPK and AKT activation stimulated by IGF-1. Presumably, for IGF-1R was dramatically up-regulated in acquired trastuzumab-resistant SKOV3-T cells, specific anti-IGF-1R antibody (LMAb1) could block the IGF-1R-driven signal cascade in order to help slower cell growth, reduce clone formation, shorten S-phase, and inhibit invasion and migration of cells.